KROS stock crashes 81% in three months after dosing with cibotercept was halted in a phase II lung disease study due to adverse pericardial effusion events.
The law firm of Kirby McInerney LLP is investigating potential claims against Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). The investigation concerns whether Keros and/or certain ...
Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...
The pericardium is very tough and unforgiving ... leads to pressure building up in the circulation of the lungs. Besides the potential for fluid or even red blood cells being forced into the small air ...
Peter Forrest, better known in the music world as onetime 24-7 Spyz frontman P. Fluid, was discovered beaten to death Monday (Jan. 13) in New York City. Per The New York Daily News, the 64-year ...